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Abstract
Background: Progranulin (PGRN) is considered to play an important role in breast cancer tumorigenesis and in inhibiting
tamoxifen-induced apoptosis. We aimed to determine whether PGRN levels are associated with breast cancer recurrence
after curative surgery.
Methodology/Principal Findings: We evaluated the associations between preoperative serum PGRN levels and breast
cancer recurrence in a cohort of 697 newly diagnosed breast cancer patients who underwent curative surgery between April
2001 and December 2004. The mean age 6 standard deviation (SD) was 4669.8 years, and all patients with hormone
receptor (HR)-positive tumors received adjuvant tamoxifen therapy. At a median follow-up of 62.2 months (range, 2.9–98.2),
89 patients (12.8%) had experienced a recurrence and 51 patients (7.3%) had died. In the HR-positive group, serum PGRN
levels were associated with recurrence according to the log-rank test for trend (p for trend =0.049). There was no
association between PGRN levels and recurrence in the HR-negative group (p for trend =0.658). Adjusted hazard ratios,
including possible confounders, revealed a linear relationship between serum PGRN levels and recurrence in the HR-positive
group (p for trend =0.049), and this association was further strengthened after excluding patients who had no lymph node
metastasis (p for trend =0.038).
Conclusions/Significance: Serum PGRN levels were clinically significant for predicting recurrence in patients with HR-
positive breast cancer during adjuvant tamoxifen therapy.
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Introduction
Breast cancer has become the most common female cancer in
many Asian and Western countries. [1] Estrogen receptor (ER) or
progesterone receptor (PR)-positive breast cancers make up
approximately three-quarters of all invasive breast cancers. [2]
Because hormone receptor (HR) status is a powerful predictor of
the efficacy of endocrine treatment, anti-hormonal therapy is given
to HR-positive patients as adjuvant treatment after curative
surgery or palliative treatment.
Although HR-positivity in breast cancer is known to be a
favorable prognostic factor, the total of number of recurrences is
similar between HR-positive and HR-negative breast cancer
patients because of the higher incidence of HR-positive breast
cancer. [2] Biomarkers to predict recurrence or interventions to
decrease the recurrence in HR-positive breast cancer are needed
for use in conjunction with adjuvant hormonal therapy.
Tamoxifen was the most common agent used in adjuvant
settings until the recent clinical application of aromatase inhibitors.
It was shown that five years of adjuvant tamoxifen treatment
significantly reduced the recurrence and mortality rates in women
with ER-positive or unknown tumors, and the benefit was largely
irrespective of age or menopausal and nodal status. [3] The
inhibitory effect of tamoxifen is observed exclusively in HR-
positive breast tumors because estrogen is the major growth
stimulator for these types of tumors.
After prolonged tamoxifen therapy, however, breast cancer
often progresses from an estrogen-sensitive state to an estrogen-
resistant state and becomes refractory to tamoxifen treatment.
Several mechanisms of developing tamoxifen resistance have
been suggested, one of which is the constitutive over-expression
of autocrine growth factors, or growth factor receptors, by tumor
cells. [4] As autocrine or paracrine growth factors increase, they
may bypass the need for ER-mediated growth stimulation in
human breast cancer cells, making anti-hormonal therapy
ineffective. Because tamoxifen has also been shown to induce
apoptosis in breast cancer cells, failure to undergo apoptosis in
response to tamoxifen could confer tamoxifen resistance. [5].
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factor (PCDGF), or granulin/epithelin precursor, is an 88-kDa
glycoprotein (GP88) composed of 7.5 cysteine-rich tandem repeats
characterized as an autocrine growth factor. [6] PGRN was
suggested to have an important role in breast cancer tumorigenesis
and to be a poor prognostic factor because it inhibits tamoxifen-
induced apoptosis and alters the cell growth response to estrogen
and tamoxifen in vivo. [7] For tumorigenesis, PGRN is known to
stimulate the proliferation and survival of several cancer cell types,
by activating mitogen-activated protein kinase (MAPK) and
phosphatidylinositol 3-kinase (PI3K) pathways. [8] The following
mechanisms underlying tamoxifen resistance conferred by PGRN
have been suggested: estrogen-independent tumor proliferation,
inhibition of tamoxifen-induced poly ADP-ribose polymerase
(PARP) cleavage, inhibition of apoptosis by down-regulating
tamoxifen-induced bcl-2 or promotion of tumor angiogenesis. [7].
In this study, we set out to determine whether PGRN levels are
associated with breast cancer recurrence after curative surgery. We
hypothesized that a higher PGRN level may be associated with
more recurrence and an increase in tamoxifen resistance in
patients with HR-positive breast cancer.
Methods
Participants
We studied a cohort of newly diagnosed breast cancer patients
who underwent surgery and consented to provide blood samples at
the National Cancer Center, Korea, between April 2001 and
December 2004. From a total of 856 patients considered for the
initial recruitment, 722 patients remained eligible after exclusion
for the following reasons: distant metastasis at diagnosis (8
patients), ductal carcinoma in situ (70 patients), cancer with
unreported ER/PR status (29 patients), male gender (1 patient),
non-epithelial origin of cancer (1 sarcoma patient), and invasive
lobular carcinoma (25 patients), which is thought to be a distinct
entity and to have a different response to adjuvant hormonal
therapy compared to invasive ductal carcinoma. [9] All diagnoses
were verified by reviewing hospital records. All patients with HR-
positive tumors received adjuvant tamoxifen therapy.
Laboratory Assessments
Venous blood samples were taken on the morning following an
overnight fast and before surgery. After centrifugation, sera were
collected and frozen at 270uC until analysis. To determine PGRN
expression levels in human plasma samples, we used the human
Progranulin ELISA kit (Adipogen Inc., Seoul, Korea) with a 1:100
dilution of the plasma samples in 1x diluent following the
manufacturer’s instructions. This ELISA kit is known to detect
only the mature human PGRN peptide (full-length PGRN), and
not its many biologically active proteolytic cleavage products. [10]
The wash solution was aspirated after each third wash to ensure
that all residual wash solution was removed. Recombinant human
PGRN provided with the ELISA kit was used as a standard. Blood
glucose levels were measured via a hexokinase enzymatic reference
method using a TBA-200FR NEO biochemical analyzer (Toshiba,
Tokyo, Japan) with a coefficient of variation (CV) of 1.3%. Plasma
insulin levels were measured using an immunoradiometric assay
(Biosource, Nivelles, Belgium) with a CV of 1.9%. The HOMA-IR
was used to estimate insulin resistance as determined by the
following formula: ((fasting insulin (mU/mL) 6 fasting glucose
(mmol/liter))/22.5. [11] Serum estradiol was measured using an
electrochemiluminescence immunoassay analyzer (Roche Modu-
lar Analytics E170; Roche, Mannheim, Germany) with a CV of
2.4%. Serum adiponectin levels were measured using an enzyme-
linked immunosorbent assay (AdipoGen, Seoul, Korea) with a CV
of 3.5%.
Immunohistochemical Staining
To assess the ER and PR expression status, immunohistochem-
ical staining was performed using tissue sections cut from formalin-
fixed, paraffin-embedded representative breast tumors. Staining
was performed using the I-View DAB detection kit and a Ventana
ES autostainer (Ventana Medical Systems, Tucson, AZ, USA)
using primary antibodies against ER and PR (both from Ventana
Medical Systems). Specimens were defined as ER- or PR-positive
when nuclear staining was observed in at least 10% of the tumor
cells tested. [12] The ER/PR status was classified into two
categories. Patients with ER-negative and PR-negative tumors
were designated as the hormone receptor-negative group (HR-
negative) and those with ER-positive or PR-positive tumors as the
hormone receptor-positive group (HR-positive).
Ethics Statement
Informed consent was obtained from all patients. This study
protocol was approved by the Institutional Review Board of the
National Cancer Center (IRB Protocol No. NCCNCS-09-220).
Statistical Methods
Patient characteristics according to HR status were summarized
as the median with range, mean with standard deviation or
percentage and compared using an unpaired t-test or chi-square
statistic, as appropriate. Median values and interquartile ranges
were presented for continuous variables with a skewed distribu-
tion, and the Wilcoxon-Mann-Whitney test was used to detect
significant differences. Distribution of serum PGRN levels was
displayed using kernel density estimate methods with Epanechni-
kov function. [13] Owing to skewed distributions and the lack of
consensus on cut-off points for discriminating abnormalities, the
PGRN level was categorized in quartiles. These categories were
defined based on the total sample. Recurrence-free survival (RFS)
was measured from the date of surgery to the day of confirmed
recurrence, death from any cause or was censored at last follow-
up. For the purpose of illustration, estimates of time to breast
cancer recurrence stratified by the quartiles of these variables are
displayed using Kaplan-Meier curves. The estimates were
analyzed using the log-rank test for trends. To adjust for possible
confounding effects of prognostic factors, we constructed a Cox
proportional hazards regression model and estimated adjusted
hazard ratios and 95% confidence intervals. The model estimated
hazard ratios after adjusting for age, BMI, tumor size, lymph node
metastasis, adjuvant chemotherapy, adiponectin, HOMA-IR and
estradiol. The proportional hazards assumption was assessed
graphically using log-rank plots of all independent variables and
statistically on the basis of Schoenfeld residuals. [14] No major
violations of the proportional hazard assumption were detected.
All analyses were performed with Stata version 11.2 (StataCorp,
College Station, TX, USA). A two-sided p-value ,0.05 was
considered statistically significant.
Results
Patient Characteristics
PGRN levels were available for 697 of 722 patients. The mean
age 6 standard deviation (SD) was 4669.8 years, and 220 patients
(31.6%) were post-menopausal women (Table 1). There was no
difference between the HR-positive and HR-negative groups in
terms of age, tumor size, positive lymph nodes or BMI. In
addition, all patients with HR-positive tumors received adjuvant
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prevalent in the HR-negative group (p=0.030), and significantly
more patients with HR-negative tumors received adjuvant
chemotherapy (p,0.001). Adjuvant chemotherapy consisted of
adriamycin/cyclophosphamide (AC) followed by taxane (T, 210
patients), cyclophosphamide/adriamycin/5-fluorouracil (CAF,
168 patients), AC (97 patients), cyclophosphamide/methotrex-
ate/5-fluorouracil (CMF, 22 patients) and others (40 patients).
Serum estradiol (p,0.001) and adiponectin (p=0.009) levels were
higher in the HR-positive patients, whereas serum PGRN
(p=0.046) and HOMA-IR (p=0.034) values were lower.
Correlation between PGRN Level and Recurrence
Median level of serum PGRN was 120.6 ng/mL (IQR, 97.8–
147.1), and the distribution of PGRN level displayed as kernel
densityestimates(Figure1).PGRNlevelwascategorizedinquartiles
because of biphasic and skewed distributions and the lack of
consensus on cut-off points for discriminating abnormalities as
previouslymentioned.Atamedianfollow-upof62.2months(range,
2.9–98.2), 89 patients (12.8%) had experienced breast cancer
recurrence. Among the 89 patients, 44 patients (9.2%) and 45
patients (20.5%) belonged to the HR-positive and HR-negative
groups,respectively.Inaddition,26patients(13.0%)and18patients
(6.5%) belonged to the HR-positive, lymph node positive and
negative groups, respectively. Among the 51 patients (7.3%) who
had died, all causes of death were identified as breast cancer. The
five-yearRFSwas89.2%(95%CI,86.9–91.4%).IntheHR-positive
group, serum PGRN levels were associated with recurrence on the
log-rank test for trend (p for trend =0.049; Figure 2A). In the HR-
positivegroup,theassociationbetweenPGRNlevelsandrecurrence
was statistically significant for patients who were metastatic lymph
node-positive (p for trend =0.047; Figure 2B), but not for patients
with no metastatic lymph nodes (p for trend =0.748). In addition,
therewasnoassociationbetweenPGRNlevelsandrecurrenceinthe
HR-negative group (p for trend =0.658).
Adjusted Hazard Ratio for Recurrence
After adjusting for possible confounders (age, BMI, tumor size,
lymph node metastasis, adjuvant chemotherapy, adiponectin,
HOMA-IR and estradiol), the Cox proportional hazards regres-
sion analysis revealed a linear relationship between serum PGRN
levels and breast cancer recurrence in the HR-positive group (p for
trend =0.049; Table 2). This association was further strengthened
after excluding patients who had no lymph node metastasis (p for
trend =0.038). Compared to the lowest PGRN quartile, the
highest quartile had a hazard ratio of 2.27 (95% CI, 0.89–5.80)
and 4.60 (95% CI, 0.99–21.3) in the HR-positive group and the
HR-positive with metastatic lymph nodes group, respectively.
There was still no statistically significant trend between PGRN
levels and recurrence in the HR-negative group (p for trend =
0.644).
Discussion
In this study, we demonstrated that preoperative serum PGRN
levels in HR-positive breast cancer patients were associated with
recurrence (p for trend ,0.05), even after adjustment for possible
mediating factors, including clinical, tumor and treatment
variables. This association was more significant when only the
patients with lymph node metastasis were evaluated.
Recently, the outcome for breast cancer patients has been
improved through the discovery of new agents such as HER2-
targeted agents and development of strategies such as tamoxifen
followed by aromatase inhibitors for adjuvant hormonal therapy.
Despite these treatment advances, about 40% of patients receiving
adjuvant tamoxifen eventually relapse and die due to their disease.
[15] Therefore, new biomarkers for predicting recurrence and
interventions aimed at decreasing recurrence in HR-positive
breast cancer are needed to supplement existing adjuvant
hormonal therapies.
Compared to HR-positive breast cancer patients, patients who
are HR-negative have fewer treatment strategies available and
need interventions aimed at decreasing recurrence or progression.
In a previous study, we showed that serum adiponectin levels and
homeostasis model assessment for insulin resistance (HOMA-IR)
values had clinical significance for predicting prognosis in HR-
negative breast cancer patients, and interventions for increasing
serum adiponectin levels and decreasing insulin resistance may be
helpful in preventing recurrence. [16] Meanwhile, PGRN has also
Table 1. Patient characteristics.
All (n=697) HR-positive (n=477) HR-negative (n=220) p-value
Age at diagnosis (mean, +/2 SD) 46.069.8 45.769.4 46.7610.7 0.210
Menopause post-menopause 220 (31.6%) 138 (28.9%) 82 (37.3%) 0.030
Tumor size $2 cm 149 (21.4%) 103 (21.6%) 46 (20.9%) 0.838
Lymph node positive 287 (41.2%) 200 (41.9%) 87 (39.5%) 0.552
Progranulin (ng/mL) (median, IQR) 120.6 (97.8–147.1) 118.1 (92.5–145.6) 123.8 (103.0–148.6) 0.046
HOMA-IR (median, IQR) 1.74 (1.38–2.47) 1.73 (1.40–2.32) 1.90 (1.40–2.62) 0.034
Estradiol (pg/mL) (median, IQR) 31.4 (14.2–80.6) 38.1 (15.6–96.7) 19.6 (12.7–64.4) ,0.001
Adiponectin (ug/mL) (median, IQR) 5.83 (3.88–7.69) 6.12 (4.13–8.01) 5.23 (3.63–7.37) 0.009
BMI (kg/m
2) (median, IQR) 23.4 (21.4–26.0) 23.2 (21.3–25.6) 23.6 (21.4–26.3) 0.461
Adjuvant CTx received 537 (77.0%) 346 (72.5%) 191 (86.8%) ,0.001
Adjuvant HRT received 477 (68.4%) 477 (100.0%) 0 (0.0%) ,0.001
Recurrence recurred 89 (12.8%) 44 (9.2%) 45 (20.5%) ,0.001
Last follow-up death 51 (7.3%) 14 (2.9%) 37 (16.8%) ,0.001
Abbreviations: HR, hormone receptor; IQR, interquartile range; HOMA-IR, homeostasis model assessment for insulin resistance; BMI, body mass index; CTx,
chemotherapy; HRT, hormone therapy.
doi:10.1371/journal.pone.0039880.t001
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as high density lipoprotein (HDL)/apolipoprotein A-I or key
regulator of inflammation that may exert its anti-inflammatory
effects partly by blocking the binding of TNF to its receptors.
[17,18].
Our findings suggest that an evaluated serum PGRN level may
assist in establishing a prognosis in HR-positive breast cancers,
regardless of tumor size, obesity and insulin resistance. Some
studies also reported that serum levels of PGRN or its expression
in tumor tissue detected immunohistochemically was associated
with the survival of patients with breast cancer. [19,20] In
addition, PGRN may be associated with resistance to trastuzumab
or letrozole. [21,22] Moreover, a recent study reported that the
inhibition of PGRN expression by antisense transfection could
inhibit breast tumor incidence and growth in nude mice and that
the administration of PGRN siRNA could restore the ability of
tamoxifen to inhibit cell proliferation. [23] These results suggest
that PGRN could be a novel biomarker and druggable target of
breast cancer. Recent studies also reported that PGRN may be a
poor prognostic factor in several malignancies, such as ovarian
cancer, [24] hepatocellular carcinoma, [25] cholangiocarcinoma
[26] and glioblastoma. [27].
Further studies regarding serum PGRN should be conducted to
determine whether serial follow-up of PGRN levels could be
predictive of breast cancer recurrence during adjuvant hormonal
treatment and whether PGRN levels can be altered and predictive
of prognosis after neoadjuvant treatment compared to PGRN
levels pre-neoadjuvant treatment. Use of a PGRN inhibitor in
addition to anti-hormonal agents or chemotherapy could provide
a new therapeutic approach for treatment and overcome drug-
resistance in patients with breast cancer who are undergoing
adjuvant, neoadjuvant or palliative treatment.
There were potential limitations in this study. The effect of
HER2 status and tumor grade, another important prognostic and
Figure 1. Distribution of serum PGRN levels in all patients as Kernel density estimate (bandwidth = 9.552). Median level of PGRN is
120.6 ng/mL (IQR, 97.8–147.1) and PGRN level is categorized in quartiles because of biphasic and skewed distributions.
doi:10.1371/journal.pone.0039880.g001
Figure 2. Kaplan-Meier cumulative recurrence curves according to the progranulin quartiles. Recurrence curves in patients with HR-
positive breast tumor (A); and HR-positive with metastatic lymph node-positive (B).
doi:10.1371/journal.pone.0039880.g002
Progranulin and Breast Cancer Recurrence
PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e39880predictive factors, were not considered because these biomarkers
were not routinely evaluated at the time of recruitment. Cancer
mortality and risk were not analyzed because only 51 deaths
occurred (7.3% of patients). Finally, a definitive conclusion with
regard to the association between PGRN and breast cancer
recurrence could not be drawn because the statistical power of our
analysis was insufficient due to the small number of patients with
recurrence and the short follow-up duration.
However, this study also has several strong points. First, our
cohort comprised a considerable number of patients with
homogeneous characteristics in terms of Asian ethnicity, invasive
ductal carcinoma histology, and the administration of adjuvant
tamoxifen treatment to all HR-positive patients. Second, several
important factors for prognosis, such as BMI, HOMA-IR and
estradiol level, were also investigated and adjusted for accordingly.
Third, to our knowledge, this is the first full article investigating
the prognostic value of PGRN for breast cancer recurrence.
Interestingly, we found that PGRN as a key regulator of
inflammation was associated with recurrence in HR-positive
breast cancer in which endocrine therapy is effective, while
adiponectin as a key regulator of insulin resistance was associated
with recurrence in HR-negative breast cancer in which endocrine
therapy is not effective. [16] These findings could provide a new
perspective on the management of breast cancer patients.
In conclusion, this study showed that preoperative serum
PGRN levels had clinical significance for predicting recurrence in
patients with HR-positive breast cancer during adjuvant tamoxifen
therapy. Further studies of PGRN are needed to determine its
prognostic value and potential treatment strategies in patients with
breast cancer.
Acknowledgments
We gratefully acknowledge the contributions of the physicians, nurses, and
other health care providers at the National Cancer Center, Korea. We also
thank the participants for their valuable contributions.
Author Contributions
Conceived and designed the experiments: DHK CYP SWO. Performed
the experiments: CYP ESL JR. Analyzed the data: DHK CYP SWO JR.
Contributed reagents/materials/analysis tools: DHK CYP SWO JR.
Wrote the paper: DHK CYP SWO. Critical revision of the manuscript:
CYP SWO ESL. Statistical expertise: CYP SWO. Obtained funding:
SWO.
References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer
statistics. CA Cancer J Clin 61: 69–90.
2. Winer EP (2005) Optimizing Endocrine Therapy for Breast Cancer. J Clin
Oncol 23: 1609–1610.
3. Early Breast Cancer Trialists’ Collaborative G (2005) Effects of chemotherapy
and hormonal therapy for early breast cancer on recurrence and 15-year
survival: an overview of the randomised trials. Lancet 365: 1687–1717.
4. Clarke R, Skaar TC, Bouker KB, Davis N, Lee YR, et al. (2001) Molecular and
pharmacological aspects of antiestrogen resistance. J Steroid Biochem Mol Biol
76: 71–84.
5. Cameron DA, Keen JC, Dixon JM, Bellamy C, Hanby A, et al. (2000) Effective
tamoxifen therapy of breast cancer involves both antiproliferative and pro-
apoptotic changes. Eur J Cancer 36: 845–851.
6. Bhandari V, Palfree RG, Bateman A (1992) Isolation and sequence of the
granulin precursor cDNA from human bone marrow reveals tandem cysteine-
rich granulin domains. Proc Natl Acad Sci USA 89: 1715–1719.
7. Tangkeangsirisin W, Hayashi J, Serrero G (2004) PC Cell-Derived Growth
Factor Mediates Tamoxifen Resistance and Promotes Tumor Growth of
Human Breast Cancer Cells. Cancer Res 64: 1737–1743.
Table 2. Adjusted hazard ratios of PGRN quartile levels for breast cancer recurrence.
HR-positive*
(n=477) Hazard ratio 95% C.I. p-value p-value for trend
Progranulin 1Q reference 0.049
Progranulin 2Q 1.67 0.64–4.32 0.294
Progranulin 3Q 2.65 1.05–6.69 0.040
Progranulin 4Q 2.27 0.89–5.80 0.085
HR-positive & LN-positive
(n=200)
Hazard ratio 95% C.I. p-value p-value for trend
Progranulin 1Q reference 0.038
Progranulin 2Q 3.19 0.65–15.6 0.153
Progranulin 3Q 4.46 0.90–22.0 0.066
Progranulin 4Q 4.60 0.99–21.3 0.051
HR-positive & LN-negative
(n=277)
Hazard ratio 95% C.I. p-value p-value for trend
Progranulin 1Q reference 0.690
Progranulin 2Q 0.92 0.24–3.50 0.899
Progranulin 3Q 1.85 0.55–6.20 0.316
Progranulin 4Q 0.92 0.20–4.24 0.918
Adjusted for age, BMI, tumor size (,2c mo r$2 cm), lymph node metastasis (*HR-positive group only), adjuvant chemotherapy (yes or no), adiponectin, HOMA-IR and
estradiol.
Abbreviations: HR, hormone receptor; LN, lymph node; Q, quartile.
doi:10.1371/journal.pone.0039880.t002
Progranulin and Breast Cancer Recurrence
PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e398808. He Z, Bateman A (2003) Progranulin (granulin-epithelin precursor, PC-cell-
derived growth factor, acrogranin) mediates tissue repair and tumorigenesis.
J Mol Med 81: 600–612.
9. Rakha EA, El-Sayed ME, Powe DG, Green AR, Habashy H, et al. (2008)
Invasive lobular carcinoma of the breast: Response to hormonal therapy and
outcomes. Eur J Cancer 44: 73–83.
10. Youn B-S, Bang S-I, Klo ¨ting N, Park JW, Lee N, et al. (2009) Serum
Progranulin Concentrations May Be Associated With Macrophage Infiltration
Into Omental Adipose Tissue. Diabetes 58: 627–636.
11. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985)
Homeostasis model assessment: insulin resistance and beta-cell function from
fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412–
419.
12. Wells CA, Sloane JP, Coleman D, Munt C, Amendoeira I, et al. (2004)
Consistency of staining and reporting of oestrogen receptor immunocytochem-
istry within the European Union–an inter-laboratory study. Virchows Archiv
445: 119–128.
13. Epanechnikov VA (1969) Non-Parametric Estimation of a Multivariate
Probability Density. Theory of Probability and its Applications 14: 153–158.
14. Schoenfeld D (1982) Partial residuals for the proportional hazards regression
model. Biometrika 69: 239–241.
15. Ring A, Dowsett M (2004) Mechanisms of tamoxifen resistance. Endocr Relat
Cancer 11: 643–658.
16. Oh S, Park C-Y, Lee E, Yoon Y, Lee E, et al. (2011) Adipokines, insulin
resistance, metabolic syndrome, and breast cancer recurrence: a cohort study.
Breast Cancer Research 13: R34.
17. Okura H, Yamashita S, Ohama T, Saga A, Yamamoto-Kakuta A, et al. (2010)
HDL/Apolipoprotein A-I Binds to Macrophage-Derived Progranulin and
Suppresses its Conversion into Proinflammatory Granulins. Journal of
Atherosclerosis and Thrombosis advpub: 1003080198–1003080198.
18. Tang W, Lu Y, Tian Q-Y, Zhang Y, Guo F-J, et al. (2011) The Growth Factor
Progranulin Binds to TNF Receptors and Is Therapeutic Against Inflammatory
Arthritis in Mice. Science 332: 478–484.
19. Tkaczuk KR, Yue B, Zhan M, Tait N, Yarlagadda L, et al. (2011) Increased
Circulating Level of the Survival Factor GP88 (Progranulin) in the Serum of
Breast Cancer Patients When Compared to Healthy Subjects. Breast Cancer
(Auckl) 5: 155–162.
20. Serrero G, Kim W, Yue B, Ioffe O, Barton R (2008) Prognostic significance of
GP88 for breast cancer recurrence. J Clin Oncol 2008; 26(suppl; abstr 22064).
21. Kim WE, Serrero G (2006) PC Cell–Derived Growth Factor Stimulates
Proliferation and Confers Trastuzumab Resistance to Her-2-Overexpressing
Breast Cancer Cells. Clin Cancer Res 12: 4192–4199.
22. Abrhale T, Brodie A, Sabnis G, Macedo L, Tian C, et al. (2011) GP88 (PC-Cell
Derived Growth Factor, progranulin) stimulates proliferation and confers
letrozole resistance to aromatase overexpressing breast cancer cells. BMC
Cancer 11: 231.
23. Tian C, Serrero G (2006) Restoration of tamoxifen response by inhibition of
PCDGF/GP88 expression in tamoxifen resistant breast cancer cells. Proc Amer
Assoc Cancer Res 2006;47(p691–692 Abstr #2940).
24. Han JJ, Yu M, Houston N, Steinberg SM, Kohn EC (2011) Progranulin is a
potential prognostic biomarker in advanced epithelial ovarian cancers. Gynecol
Oncol 120: 5–10.
25. Ho JC, Ip YC, Cheung ST, Lee YT, Chan KF, et al. (2008) Granulin-epithelin
precursor as a therapeutic target for hepatocellular carcinoma. Hepatology 47:
1524–1532.
26. Frampton G, Invernizzi P, Bernuzzi F, Pae HY, Quinn M, et al. (2011) DOI:
10.1136/gutjnl-2011-300643) Interleukin-6-driven progranulin expression in-
creases cholangiocarcinoma growth by an Akt-dependent mechanism. Gut.
27. Wang M, Li G, Yin J, Lin T, Zhang J (2011) Progranulin overexpression predicts
overall survival in patients with glioblastoma. Medical Oncology: 1–9.
Progranulin and Breast Cancer Recurrence
PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e39880